Credit Suisse analyst Richard Law CFA maintained a Hold rating on Homology Medicines (FIXX – Research Report) today and set a price target of $2.10. The company's shares closed last Monday at $1.44, close to its 52-week low of $1.39. According to TipRanks.com, CFA is a 1-star analyst with an average return of -12.1% and a 20.0% success rate. CFA covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company, Monte Rosa Therapeutics, and Crispr Therapeutics AG. Currently, the analyst consensus on Homology Medicines is a Moderate Buy with an average price target of $10.64.
https://www.tipranks.com/news/blurbs/homology-medicines-fixx-gets-a-hold-rating-from-credit-suisse?utm_source=advfn.com&utm_medium=referral
Homology Medicines (NASDAQ:FIXX)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Homology Medicines Charts.
Homology Medicines (NASDAQ:FIXX)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Homology Medicines Charts.